Zobrazeno 1 - 5
of 5
pro vyhledávání: '"James Araujo"'
Autor:
Ribeiro, Dimas Mendes, Pinheiro, Frank James Araujo, Pelacani, Claudinéia Regina, de Lana Souza, Braulio Maia, Mapeli, Ana Maria, Müller, Caroline, Cabrini, Elaine Cristina, Coelho, Tales Graciano, Rocha, Glayton Botelho, Barros, Raimundo Santos
Publikováno v:
Seed Technology, 2008 Jan 01. 30(1), 76-81.
Externí odkaz:
https://www.jstor.org/stable/23433373
Autor:
John B. Lowe, James Araujo, Patricia Siguenza, John G. Matthews, Elaine Murray, Melissa Cheu, An Song, Saloumeh K Fischer, Kun Peng, Dana McClintock
Publikováno v:
The AAPS journal. 19(1)
Host cell proteins are manufacturing process-related impurities that may co-purify with the product despite extensive efforts to optimize the purification process. The risks associated with these impurities can vary and may be patient and/or therapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1f5220756c481afcd9ca74c082b985e
https://pubmed.ncbi.nlm.nih.gov/27739010
https://pubmed.ncbi.nlm.nih.gov/27739010
Publikováno v:
Anais do Congresso de Iniciação Científica da Unicamp.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0435d36f3667fe850645628a76be93b
https://doi.org/10.19146/pibic-2015-36960
https://doi.org/10.19146/pibic-2015-36960
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 55(5)
Protein therapeutics may elicit an anti-therapeutic antibody (ATA) response in patients. This response depends on a number of factors including patient population, disease state, route of delivery or characteristics specific to the product. Therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2fbfd0757ba791219d78d79b9c6e92c
https://pubmed.ncbi.nlm.nih.gov/21466939
https://pubmed.ncbi.nlm.nih.gov/21466939
Autor:
Vanessa Shiu, Valerie Quarmby, John B. Lowe, Mauricio Maia, Amy Oldendorp, Jihong Yang, Mike Reich, Jacques Gaudreault, Henry B. Lowman, James Araujo, Samantha Lien
Publikováno v:
Experimental eye research. 85(4)
Neovascular age-related macular degeneration (AMD) is the leading cause of blindness in older adults in the Western world. Ranibizumab (Lucentis), a humanized antibody fragment directed against vascular endothelial growth factor (VEGF-A), was recentl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb17dd8c9a0e9601aba68a6ecea577c9
https://pubmed.ncbi.nlm.nih.gov/17714704
https://pubmed.ncbi.nlm.nih.gov/17714704